Previous 10 | Next 10 |
iBio (IBIO) +33% on COVID-19 study update.Orgenesis (ORGS) +11% on Q1 results.Chemomab Therapeutics (CMMB) +12%.T2 Biosystems, Inc. (TTOO) +11% on Q1 results.ViewRay (VRAY) +12%.Epizyme (EPZM) +11% on Q1 results.CureVac N.V. (CVAC) +9%.Roku (ROKU) +9% on Q1 results.Da...
Orgenesis (ORGS) jumps 11% premarket after announcing financial results for the first quarter ended March 31, 2021.The company reported Q1 total revenues of $9.4M, an increase of 400% over prior year.ORGS achieved positive operating profit of $0.08M for Q1 vs. operating loss of $6.7...
Achieves operating profit for the first quarter of 2021 Cash and cash equivalents of $41.8 million as of March 31, 2021 Orgenesis to host conference call today at 8:30 AM ET GERMANTOWN, Md., May 07, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) ...
Gainers: Stealth BioTherapeutics (MITO) +45%, Biofrontera (BFRA) +18%, BioCryst Pharmaceuticals (BCRX) +15%, Orgenesis (ORGS) +12%, GT Biopharma (GTBP) +4%.Losers: Regional Health Properties (RHE) -24%, VYNE Therapeutics (VYNE) ...
Orgenesis (ORGS) has been granted Investigational Device Exemption ((IDE)) approval by the U.S. FDA to conduct a first-in-human feasibility study of the Tissue Genesis Icellator to treat Acute Respiratory Distress Syndrome ((ARDS)) resulting from COVID-19 infection.Shares up more th...
IDE approval provides important validation of clinical development plans for the Icellator 2 GERMANTOWN, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company wo...
GERMANTOWN, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a con...
Orgenesis shares rise ([[ORGS]] +2.3%) after announcing that it has entered a collaboration with the Bambino Gesù Children's Hospital in Rome to establish a Point of Care Cell Therapy center.Process work will be focused on supporting clinical trials related to therapies de...
Checking our POWR Ratings service before you buy a stock is a great way to get a second opinion. Stocks that are rated a Buy or Strong Buy are likely to outperform in the months ahead, while stocks that are rated Sell or Strong Sell are likely to underperform in the months ahead. That's why y...
GERMANTOWN, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, announces that it has entered a collabora...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 2.7% to $127.255 on volume of 88,797,787 shares Ascent Solar Technologies Inc (ASTI) rose 9.6% to $0.1183 on volume of 88,651,038 shares Crown Electrokinetics Corp. (CRKN) fell 19.0% to $0.040499 on volu...